Cargando…
The European Medicines Agency assessment of mavacamten as treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542624/ https://www.ncbi.nlm.nih.gov/pubmed/37482673 http://dx.doi.org/10.1093/eurheartj/ehad429 |
| _version_ | 1785114131091685376 |
|---|---|
| author | DeVries, J Hans Irs, Alar Hillege, Hans L |
| author_facet | DeVries, J Hans Irs, Alar Hillege, Hans L |
| author_sort | DeVries, J Hans |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10542624 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-105426242023-10-03 The European Medicines Agency assessment of mavacamten as treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients DeVries, J Hans Irs, Alar Hillege, Hans L Eur Heart J CardioPulse Oxford University Press 2023-07-24 /pmc/articles/PMC10542624/ /pubmed/37482673 http://dx.doi.org/10.1093/eurheartj/ehad429 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
| spellingShingle | CardioPulse DeVries, J Hans Irs, Alar Hillege, Hans L The European Medicines Agency assessment of mavacamten as treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients |
| title | The European Medicines Agency assessment of mavacamten as treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients |
| title_full | The European Medicines Agency assessment of mavacamten as treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients |
| title_fullStr | The European Medicines Agency assessment of mavacamten as treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients |
| title_full_unstemmed | The European Medicines Agency assessment of mavacamten as treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients |
| title_short | The European Medicines Agency assessment of mavacamten as treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients |
| title_sort | european medicines agency assessment of mavacamten as treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients |
| topic | CardioPulse |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542624/ https://www.ncbi.nlm.nih.gov/pubmed/37482673 http://dx.doi.org/10.1093/eurheartj/ehad429 |
| work_keys_str_mv | AT devriesjhans theeuropeanmedicinesagencyassessmentofmavacamtenastreatmentofsymptomaticobstructivehypertrophiccardiomyopathyinadultpatients AT irsalar theeuropeanmedicinesagencyassessmentofmavacamtenastreatmentofsymptomaticobstructivehypertrophiccardiomyopathyinadultpatients AT hillegehansl theeuropeanmedicinesagencyassessmentofmavacamtenastreatmentofsymptomaticobstructivehypertrophiccardiomyopathyinadultpatients AT devriesjhans europeanmedicinesagencyassessmentofmavacamtenastreatmentofsymptomaticobstructivehypertrophiccardiomyopathyinadultpatients AT irsalar europeanmedicinesagencyassessmentofmavacamtenastreatmentofsymptomaticobstructivehypertrophiccardiomyopathyinadultpatients AT hillegehansl europeanmedicinesagencyassessmentofmavacamtenastreatmentofsymptomaticobstructivehypertrophiccardiomyopathyinadultpatients |